Bob van Gemen

Bob has >30 years of experience in the healthcare space being CEO of biotech companies or running business units in large multination companies. Most recently was CEO of Viroclinics where he grew the company from 40 to 400 people and revenues from €5M to €75M. Under his guidance, Viroclinics Inc. was established in the USA and the company acquired DDL Diagnostics to accelerate growth. Viroclinics partnered with 3 private equity funds of increasing size to enable organic and accelerated growth of the company, recently Viroclinics was acquired by Cerba Healthcare.

Bob’s scientific experience includes molecular biology, virology, and (pre)clinical study programs for the development of antivirals and vaccines for numerous respiratory infections.

Bob van Gemen has a Master's in Biology from the Free University of Amsterdam and a Ph.D. in molecular biology from the University of Leiden.